Design. Analysis. Interpretation. Reporting.

From preclinical studies to epidemiology, the Department of Biostatistics and Bioinformatics at Roswell Park develops cutting-edge methods and software tools focused on cancer research.

With expertise across biology, medicine, statistics, mathematics and computer science, our faculty guide and participate in basic, translational, epidemiological and clinical trials research. Our department chair is Alan Hutson, Ph.D.

Meet our facultyContact usSupport our research

Dr. Alan Hutson, Chair of Biostatistics and Bioinformatics

“Our goal with the work we do every day at Roswell Park is to assess what the most pressing priorities are in data utilization and management, and then address those challenges and opportunities so we can support the biggest oncology advances of the next decade.”

Data-driven expertise across five divisions

Biostatistics and Statistical Genomics

Developing, overseeing, implementing, analyzing, publishing and reporting Roswell Park’s scientific studies. Co-directed by Dr. Qianqian Zhu and Dr. Han Yu.

Learn more

Bioinformatics

Designing, analyzing, and interpretating genomics, proteomics, and other high-resolution, high-throughput based studies. Led by Dr. Song Liu.

Learn more

Biomedical Research Information

Creating innovative informatics tools that optimize data acquisition, data quality and data curation. Led by Dr. Sarah Mullin.

Learn more

Bioconductor Project

Providing tools for the analysis and comprehension of high-throughput genomic data. Led by Dr. Martin Morgan.

Learn more

Clinical Trial Development Division (CTDD)

Working with investigators and sponsors to develop, conduct, monitor and report clinical trials. Led by Angela Kuras.

Learn more

Dr. Martin Morgan sits in his office.

“The r/Bioconductor project enables researchers worldwide to develop, share and use leading-edge statistical approaches and to place the insights we gain from these tools into their appropriate contexts so we can support medical research that’s both more accurate and more actionable.”

Unmatched clinical trials management

The Clinical Trial Development Division (CTDD), under the direction of Virginia Filiaci, PhD, works with investigators and sponsors to develop, conduct, monitor and report clinical trials. Our experienced team provides full statistical, data management, project management and quality assurance collaboration on multi-center clinical trials.

Multi-center cancer clinical trials

450+

Patient registrations

113,000+

Phase 3 trials

120+

CTDD also offers an efficient and cost-effective budgeting process and access to a 21 CFR Part 11 compliant electronic data collection option for NCI funded clinical trials.

Far-reaching research networks

Roswell Park’s Department of Biostatistics and Bioinformatics also houses several large-scale collaboration projects, including participation in the National Cancer Institute’s Cancer Moonshot Initiative.

NRG Oncology Logo

NRG Oncology Network

Conducting practice-changing multi-institutional clinical and translational research

Learn more

Immunology Oncology Translational Network

Advancing research progress to improve immunotherapy and immunoprevention

Learn more
ARTNet

Acquired Resistance to Therapy Network

ARTNet focuses on the mechanistic bases of acquired resistance to cancer therapies and disease recurrence.

Learn more
NCI CAP-IT

Cancer Prevention-Interception Targeted Agent Discovery Program

CAP-IT seeks to establish a new discovery research paradigm in cancer prevention.

Learn more

Training the next generation of scientists

In addition to our research and community outreach, the Department of Biostatistics and Bioinformatics is actively involved in hands-on teaching with Master’s and PhD students in our highly competitive graduate studies program.

Our faculty also work closely with the University at Buffalo’s Biostatistics Department, training and mentoring numerous UB doctoral candidates.

Our multidisciplinary education model allows students a unique immersive experience, preparing them for successful careers as independent investigators. 

EducationMeet our faculty

Selected publications

  • Annapragada A, Sikora AG, Marathe H, Liu S (TII), Demetriou M, Fong L, Gao J, Kufe D, Morris ZS, Vilar E, Sharon E, Hutson A (DT), Odunsi K. The Cancer Moonshot Immuno-Oncology Translational Network (IOTN) at age 5: Accelerating Cancer Immunotherapies. J Natl Cancer Inst. 2023 AUG 12; . DOI: 10.1093/jnci/djad151. 2023 Aug 12. PubMed PMID: 37572314.
  • McGray AJR, Chiello JL, Tsuji T, Long M (CSB), Maraszek K, Gaulin N, Rosario SR (CSB), Hess SM, Abrams SI (TII), Kozbor D (TII), Odunsi K, Zsiros E (TII). BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control. J Immunother Cancer. 2023 JUN 01; 11(6). DOI: 10.1136/jitc-2023-006863. 2023 Jun 23. PubMed PMID: 37647218; PMCID: PMC10314690.
  • Li F (DT), Ling X, Chakraborty S (DT), Fountzilas C (DT), Wang J (DT), Jamroze A, Liu X, Kalinski P (TII), Tang DG (DT). Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence. J Exp Clin Cancer Res. 2023 AUG 19; 42(1):213. DOI: 10.1186/s13046-023-02787-x. 2023 Aug 19. PubMed PMID: 37596619; PMCID: PMC10439624.
  • Rawat C, Ben-Salem S, Singh N, Chauhan G, Rabljenovic A, Vaghela V, Venkadakrishnan VB, Macdonald JD, Dahiya UR, Ghanem Y, Bachour S, Su Y, DePriest AD, Lee S, Muldong M, Kim HT, Kumari S, Valenzuela MM, Zhang D, Hu Q, Cortes Gomez E, Dehm SM, Zoubeidi A, Jamieson CAM, Nicolas M, McKenney J, Willard B, Klein EA, Magi-Galluzzi C, Stauffer SR, Liu S (TII), Heemers HV. Prostate cancer progression relies on the mitotic kinase citron kinase. Cancer Res. 2023 OCT 06; . DOI: 10.1158/0008-5472.CAN-23-0883. 2023 Oct 6. PubMed PMID: 37801613.
  • Wu R, Oshi M, Asaoka M, Yan L (PS), Benesch MGK, Khoury T, Nagahashi M, Miyoshi Y, Endo I, Ishikawa T, Takabe K (DT). Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer. Ann Surg. 2023 OCT 01; 278(4):587-597. DOI: 10.1097/SLA.0000000000005954. 2023 Jun 15. PubMed PMID: 37318852; PMCID: PMC10481934.
  • Boucher Y, Posada JM, Subudhi S, Kumar AS, Rosario SR (CSB), Gu L, Kumra H, Mino-Kenudson M, Talele NP, Duda DG, Fukumura D, Wo JY, Clark JW, Ryan DP, Fernandez-Del Castillo C, Hong TS, Pittet MJ, Jain RK. Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer. Clin Cancer Res. 2023 APR 14; 29(8):1605-1619. DOI: 10.1158/1078-0432.CCR-22-1630. PubMed PMID: 36749873; PMCID: PMC10106451.
  • Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S. Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. Clin Cancer Res. 2023 MAY 01; 29(9):1698-1707. DOI: 10.1158/1078-0432.CCR-22-2032. PubMed PMID: 36595569; PMCID: PMC10150250.
  • Ge Y, Chen X, Nan N, Bard J, Wu F, Yergeau D, Liu T (DT), Wang J, Mu X. Key transcription factors influence the epigenetic landscape to regulate retinal cell differentiation. Nucleic Acids Res. 2023 MAR 21; 51(5):2151-2176. DOI: 10.1093/nar/gkad026. PubMed PMID: 36715342; PMCID: PMC10018358.
  • Luzhin A, Rajan P, Safina A, Leonova K, Stablewski A (TII), Wang J (DT), Robinson D, Isaeva N, Kantidze O, Gurova K (CSB). Comparison of cell response to chromatin and DNA damage. Nucleic Acids Res. 2023 OCT 19; . DOI: 10.1093/nar/gkad865. 2023 Oct 19. PubMed PMID: 37855682.
  • Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, Mechtler LL, Peereboom DM, Hutson AD (DT), Withers HG, Liu S (TII), Belal AN, Qiu J, Mogensen KM, Dharma SS, Dhawan A, Birkemeier MT, Casucci DM, Ciesielski MJ (TII), Fenstermaker RA (TII). Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol. 2023 MAR 01; 41(7):1453-1465. DOI: 10.1200/JCO.22.00996. 2022 Dec 15. PubMed PMID: 36521103; PMCID: PMC9995096.
  • Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 JUN 08; 388(23):2159-2170. DOI: 10.1056/NEJMoa2302312. 2023 Mar 27. PubMed PMID: 36972022; PMCID: PMC10351614.
  • Krishnan K, Shi T, Yu H (CSB), Hageman Blair R. Integrated Graph Propagation and Optimization with Biological Applications. Pac Symp Biocomput. 2023 JAN 01; 28:169-180. PubMed PMID: 36540974.
  • Luzhin A, Rajan P, Safina A, Leonova K, Stablewski A (TII), Wang J (DT), Pal M, Kantidze O, Gurova K (CSB). Comparison of cell response to chromatin and DNA damage. bioRxiv. 2023 JAN 18; . DOI: 10.1101/2023.01.17.524424. 2023 Jan 18. PubMed PMID: 36711582; PMCID: PMC9882266.
  • Abdelfatah E, Long MD (CSB), Kajihara R, Oba T, Yamauchi T, Chen H, Sarkar J, Attwood K (DT), Matsuzaki J, Segal BH (TII), Dy GK (DT), Ito F. Predictive and Prognostic Implications of Circulating CX3CR1+ CD8+ T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy. Cancer Res Commun. 2023 MAR 01; 3(3):510-520. DOI: 10.1158/2767-9764.CRC-22-0383. 2023 Mar 30. PubMed PMID: 37009132; PMCID: PMC10060186.
  • Kirk JS, Wang J, Tracz A, Long M (CSB), Rosario SR (CSB), Ji Y, Kumar R, Liu X, Singh PK, Puzanov I (DT), Chatta G (DT), Cheng Q, Huang J, Wrana JL, Lovell J, Yu H (CSB), Liu S (TII), Shen MM, Liu T (DT), Tang DG (DT). Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells. bioRxiv. 2023 MAR 06; . DOI: 10.1101/2023.03.03.530998. 2023 Mar 6. PubMed PMID: 36945493; PMCID: PMC10028794.
  • Afiaz A, Ivanov AA, Chamberlin J, Hanauer D, Savonen CL, Goldman MJ, Morgan M (TII), Reich M, Getka A, Holmes A, Pati S, Knight D, Boutros PC, Bakas S, Caporaso JG, Del Fiol G, Hochheiser H, Haas B, Schloss PD, Eddy JA, Albrecht J, Fedorov A, Waldron L, Hoffman AM, Bradshaw RL, Leek JT, Wright C. Evaluation of software impact designed for biomedical research: Are we measuring what's meaningful? ArXiv. 2023 JUN 05; . 2023 Jun 5. PubMed PMID: 37332562; PMCID: PMC10274942.
  • Padgett LR, Shinkle MR, Rosario S (CSB), Stewart TM, Foley JR, Casero RA, Park MH, Chung WK, Mastracci TL. Deoxyhypusine synthase mutations alter the post-translational modification of eukaryotic initiation factor 5A resulting in impaired human and mouse neural homeostasis. HGG Adv. 2023 JUL 13; 4(3):100206. DOI: 10.1016/j.xhgg.2023.100206. 2023 May 18. PubMed PMID: 37333770; PMCID: PMC10275725.
  • Hutson A (DT), Yu H (CSB), Attwood K (DT). Leveraging Homologous Hypotheses for Increased Efficiency in Tumor Growth Curve Testing. Res Sq. 2023 AUG 17; . DOI: 10.21203/rs.3.rs-3242375/v1. 2023 Aug 17. PubMed PMID: 37645958; PMCID: PMC10462185.
  • Flynn PA, Long MD (CSB), Kosaka Y, Mulkey JS, Coy JL, Agarwal A, Lind EF. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency. bioRxiv. 2023 SEP 22; . DOI: 10.1101/2023.09.19.558512. 2023 Sep 22. PubMed PMID: 37781631; PMCID: PMC10541139.
  • Takeshita T, Iwase H, Wu R, Ziazadeh D, Yan L (PS), Takabe K (DT). Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer Using Nine-Gene Expression Signature. World J Oncol. 2023 OCT 01; 14(5):406-422. DOI: 10.14740/wjon1700. 2023 Sep 20. PubMed PMID: 37869243; PMCID: PMC10588506.
  • Shadpour S, Shafqat A, Toy S, Jing Z, Attwood K (DT), Moussavi Z, Shafiei SB. Developing cognitive workload and performance evaluation models using functional brain network analysis. NPJ Aging. 2023 OCT 06; 9(1):22. DOI: 10.1038/s41514-023-00119-z. 2023 Oct 6. PubMed PMID: 37803137; PMCID: PMC10558559.
  • Vylegzhanina A, Bespalov I, Novototskaya-Vlasova K, Hall BM, Gleiberman A, Yu H (CSB), Leontieva O, Leonova KI, Kurnasov O, Osterman AL, Dy GK (DT), Komissarov AA, Vasilieva E, Gehlhausen JR, Iwasaki A, Ambrosone CB (PS), Tsuji T, Matsuzaki J, Odunsi K, Andrianova E, Gudkov AV (CSB). Cancer relevance of circulating antibodies against LINE-1 antigens in humans. Cancer Res Commun. 2023 OCT 23; . DOI: 10.1158/2767-9764.CRC-23-0289. 2023 Oct 23. PubMed PMID: 37870410.
  • Liu JF, Brady MF, Matulonis UA, Miller A (TII), Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 JUL 01; 40(19):2138-2147. DOI: 10.1200/JCO.21.02011. 2022 Mar 15. PubMed PMID: 35290101; PMCID: PMC9242406.
  • Gershenson DM, Miller A (TII), Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O'Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022 FEB 05; 399(10324):541-553. DOI: 10.1016/S0140-6736(21)02175-9. PubMed PMID: 35123694; PMCID: PMC8819271.
  • Pokhare S, Sharma UC, Attwood K (DT), Mansoor S. Clinical Significance of Galectin-3 Expression in Squamous Cell Carcinoma of Lung. J Cancer Sci Clin Ther. 2022 JAN 01; 6(3):322-327. DOI: 10.26502/jcsct.5079169. 2022 Aug 22. PubMed PMID: 36081447; PMCID: PMC9451108.
  • Hagoel TJ, Cortes Gomez E, Gupta A (DT), Twist CJ (DT), Kozielski R, Martin JC, Gao L, Kuechle J, Singh PK, Lynch M, Wei L (CSB), Liu S (TII), Wang J (DT), Ohm JE (CSB). Clinicopathologic and molecular analysis of a BCOR-CCNB3 undifferentiated sarcoma of the kidney reveals significant epigenetic alterations. Cold Spring Harb Mol Case Stud. 2022 JAN 01; 8(1). DOI: 10.1101/mcs.a005942. 2022 Jan 10. PubMed PMID: 34819304; PMCID: PMC8744494.
  • Elkin PL, Resendez S, Mullin S (CSB), Troen BR, Mammen MJ, Chang S, Franklin G, McCray W, Brown SH. Leukotriene inhibitors with dexamethasone show promise in the prevention of death in COVID-19 patients with low oxygen saturations. J Clin Transl Sci. 2022 JAN 01; 6(1):e74. DOI: 10.1017/cts.2022.401. 2022 May 16. PubMed PMID: 35836784; PMCID: PMC9274389.
  • Schatz MC, Philippakis AA, Afgan E, Banks E, Carey VJ, Carroll RJ, Culotti A, Ellrott K, Goecks J, Grossman RL, Hall IM, Hansen KD, Lawson J, Leek JT, Luria AO, Mosher S, Morgan M (TII), Nekrutenko A, O'Connor BD, Osborn K, Paten B, Patterson C, Tan FJ, Taylor CO, Vessio J, Waldron L, Wang T, Wuichet K. Inverting the model of genomics data sharing with the NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space. Cell Genom. 2022 JAN 12; 2(1). DOI: 10.1016/j.xgen.2021.100085. 2022 Jan 13. PubMed PMID: 35199087; PMCID: PMC8863334.
  • Pugh SL, Brown PD, Enserro D. Missing repeated measures data in clinical trials. Neurooncol Pract. 2022 FEB 01; 9(1):35-42. DOI: 10.1093/nop/npab043. 2021 Jul 16. PubMed PMID: 35096402; PMCID: PMC8789297.
  • Athans S, Krishnan N, Ramakrishnan S, Cortes Gomez E, Lage-Vickers S, Rak M, Kazmierczak Z, Ohm J (CSB), Attwood K (DT), Wang J (DT), Woloszynska A (DT). STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer. Cancer Res Commun. 2022 OCT 01; 2(10):1129-1143. DOI: 10.1158/2767-9764.crc-22-0155. 2022 Oct 6. PubMed PMID: 36275363; PMCID: PMC9583756.

Contact us

Meegan Michalek Becker, MA
Department Administrator
Phone: 716-845-1090
Email: Meegan.Becker@RoswellPark.org

Lauren Sibolski
Administrative Assistant
Phone: 716-845-2704
Email: Lauren.Sibolski@RoswellPark.org